This is an unofficial archive of PsychonautWiki as of 2025-08-11T15:14:44Z. Content on this page may be outdated, incomplete, or inaccurate. Please refer to the original page for the most up-to-date information.
Lisdexamfetamine: Difference between revisions
>LockPicker Undo revision 142427 by Thomasdequincey (talk) - Restored previous edits |
>Thomasdequincey No edit summary |
||
| Line 82: | Line 82: | ||
*'''[[Effect::Anxiety]]''' - This effect occurs more frequently on the offset phase of the experience. | *'''[[Effect::Anxiety]]''' - This effect occurs more frequently on the offset phase of the experience. | ||
*'''[[Effect::Creativity enhancement]]''' | *'''[[Effect::Creativity enhancement]]''' | ||
*'''[[Effect::Compulsive redosing]]''' - Due to the slow come up of lisdexamfetamine, the full effects may not be felt for up to 3 hours after consumption, causing some to redose during the come up. | *'''[[Effect::Compulsive redosing]]''' - Due to the slow come up of lisdexamfetamine, the full effects may not be felt for up to 3 hours after consumption, causing some to redose during the come up. Compulsive redosing is more common if heavy doses are taken. | ||
*'''[[Effect::Ego inflation]]''' | *'''[[Effect::Ego inflation]]''' | ||
*'''[[Effect::Emotion suppression]]''' - This effect is more commonly reported with lisdexamfetamine, in comparison to other [[amphetamine]]s such as [[dextroamphetamine]] and [[methamphetamine]]. It is usually most intense at low and common doses. | *'''[[Effect::Emotion suppression]]''' - This effect is more commonly reported with lisdexamfetamine, in comparison to other [[amphetamine]]s such as [[dextroamphetamine]] and [[methamphetamine]]. It is usually most intense at low and common doses. | ||
| Line 116: | Line 116: | ||
*'''[[Effect::Wakefulness]]''' | *'''[[Effect::Wakefulness]]''' | ||
Making sure to eat and | Making sure to eat well and to hydrate are recommended to decrease the severity of comedown effects. Using mild sedatives is also a common strategy for stimulant comedowns. | ||
}} | }} | ||
| Line 122: | Line 122: | ||
===Experience reports=== | ===Experience reports=== | ||
There are currently no anecdotal reports which describe the effects of this compound within our [[experience index]]. Additional experience reports can be found here: | There are currently no anecdotal reports which describe the effects of this compound within our [[experience index]]. Additional experience reports can be found here: | ||
* [https://erowid.org/experiences/subs/exp_Lisdexamfetamine.shtml Erowid Experience Vaults: Lisdexamfetamine] | |||
*[https://erowid.org/experiences/subs/exp_Lisdexamfetamine.shtml Erowid Experience Vaults: Lisdexamfetamine] | |||
==Toxicity and Harm Potential== | ==Toxicity and Harm Potential== | ||
| Line 150: | Line 151: | ||
*'''Norway''': Lisdexamfetamine is a Class A drug under particularly strict control. | *'''Norway''': Lisdexamfetamine is a Class A drug under particularly strict control. | ||
*'''Sweden''': Lisdexamfetamine is a Class II narcotic, with strict requirements for prescription. It has been placed under "utökad övervakning" (extended surveillance).<ref name="swe">http://www.fass.se/LIF/product?userType=2&nplId=20140730000117</ref> | *'''Sweden''': Lisdexamfetamine is a Class II narcotic, with strict requirements for prescription. It has been placed under "utökad övervakning" (extended surveillance).<ref name="swe">http://www.fass.se/LIF/product?userType=2&nplId=20140730000117</ref> | ||
*'''Switzerland''': Lisdexamphetamine is a controlled substance as of October 1, 2014 specifically named under Verzeichnis A. Medicinal use is permitted.<ref>{{cite web|url=https://www.admin.ch/opc/de/classified-compilation/20101220/index.html|title=Verordnung des EDI über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien|publisher=Bundeskanzlei [Federal Chancellery of Switzerland]|access-date=January 1, 2020|language=de}}</ref> | *'''Switzerland''': Lisdexamphetamine is a controlled substance as of October 1, 2014 specifically named under Verzeichnis A. Medicinal use is permitted.<ref>{{cite web|url=https://www.admin.ch/opc/de/classified-compilation/20101220/index.html|title=Verordnung des EDI über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien|publisher=Bundeskanzlei [Federal Chancellery of Switzerland]|access-date=January 1, 2020|language=de}}</ref> | ||
*'''United Kingdom''': Lisdexamfetamine is a Class B scheduled drug.{{citation needed}} | *'''United Kingdom''': Lisdexamfetamine is a Class B scheduled drug.{{citation needed}} | ||
*'''United States''': Lisdexamfetamine is a Schedule II controlled drug.<ref>https://www.law.cornell.edu/uscode/text/21/812#b_4</ref> | *'''United States''': Lisdexamfetamine is a Schedule II controlled drug.<ref>https://www.law.cornell.edu/uscode/text/21/812#b_4</ref> | ||
==See also== | ==See also== | ||
*[[Responsible use]] | *[[Responsible use]] | ||
*[[Stimulants]] | *[[Stimulants]] | ||
| Line 161: | Line 163: | ||
==External links== | ==External links== | ||
*[http://en.wikipedia.org/wiki/Lisdexamfetamine Lisdexamfetamine (Wikipedia)] | *[http://en.wikipedia.org/wiki/Lisdexamfetamine Lisdexamfetamine (Wikipedia)] | ||
*[https://isomerdesign.com/PiHKAL/explore.php?id=10644 Lisdexamfetamine (Isomer Design)] | *[https://isomerdesign.com/PiHKAL/explore.php?id=10644 Lisdexamfetamine (Isomer Design)] | ||
| Line 167: | Line 170: | ||
==Literature== | ==Literature== | ||
*Galli, A., Poulsen, N.W., Sulzer, D., & Sonders, M.S. (2005). Mechanisms of neurotransmitter release by amphetamines: a review. Progress in Neurobiology, 75 6, 406-33. https://doi.org/10.1016/j.pneurobio.2005.04.003 | *Galli, A., Poulsen, N.W., Sulzer, D., & Sonders, M.S. (2005). Mechanisms of neurotransmitter release by amphetamines: a review. Progress in Neurobiology, 75 6, 406-33. https://doi.org/10.1016/j.pneurobio.2005.04.003 | ||
*Berman, S. M., Kuczenski, R., McCracken, J. T., & London, E. D. (2009). Potential adverse effects of amphetamine treatment on brain and behavior: a review. Molecular Psychiatry, 14(2), 123. https://doi.org/10.1038/mp.2008.90. | *Berman, S. M., Kuczenski, R., McCracken, J. T., & London, E. D. (2009). Potential adverse effects of amphetamine treatment on brain and behavior: a review. Molecular Psychiatry, 14(2), 123. https://doi.org/10.1038/mp.2008.90. | ||